Cargando…
The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
We herein report the case of a hemodialysis patient whose response to an erythropoiesis-stimulating agent (ESA) improved following the resection of thyroid cancer. Her hemoglobin level remained below 7 g/dL, despite the use of ESA. During the search for the causes of her hyporesponsiveness to ESA, p...
Autores principales: | Nagata, Soichiro, Ikegaya, Naoki, Ogino, Shuhei, Uchida, Shinichi, Itaya, Mikiko, Momita, Aoi, Shinozaki, Shingo, Ohura, Masaharu, Kuriki, Ken, Kono, Satoshi, Miyajima, Hiroaki, Hishida, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457924/ https://www.ncbi.nlm.nih.gov/pubmed/28381747 http://dx.doi.org/10.2169/internalmedicine.56.7455 |
Ejemplares similares
-
Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020) -
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020) -
Aceruloplasminemia with Abnormal Compound Heterozygous Mutations Developed Neurological Dysfunction during Phlebotomy Therapy
por: Watanabe, Maki, et al.
Publicado: (2018) -
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020) -
Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)